BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32964074)

  • 21. Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters.
    Lee H; Chung YS; Lee JH; Lee KY; Hwang KH
    World J Clin Cases; 2022 Jan; 10(1):155-165. PubMed ID: 35071515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.
    Park T; Lee S; Park S; Lee E; Pahk K; Rhee S; Cho J; Kim C; Eo JS; Choe JG; Kim S
    Nucl Med Mol Imaging; 2015 Mar; 49(1):42-51. PubMed ID: 25774237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of
    Li S; Lin D; Tang M; Liu D; Lyu Q; Zhang J
    J Gastrointest Oncol; 2022 Apr; 13(2):637-646. PubMed ID: 35557562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
    Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
    J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
    Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
    Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.
    Jin F; Zhu H; Fu Z; Kong L; Yu J
    Onco Targets Ther; 2016; 9():2993-9. PubMed ID: 27284249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT.
    Razak HR; Geso M; Abdul Rahim N; Nordin AJ
    J Med Imaging Radiat Oncol; 2011 Dec; 55(6):556-62. PubMed ID: 22141602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
    Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
    Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.
    Lee JK; Min KJ; So KA; Kim S; Hong JH
    J Ovarian Res; 2014 Feb; 7():15. PubMed ID: 24499648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of visual analysis versus dual time-point imaging with
    Grisanti F; Zulueta J; Rosales JJ; Morales MI; Sancho L; Lozano MD; Mesa-Guzmán M; García-Velloso MJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(3):155-160. PubMed ID: 33781718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination.
    Stangierski A; Woliński K; Czepczyński R; Czarnywojtek A; Lodyga M; Wyszomirska A; Janicka-Jedyńska M; Bączyk M; Ruchała M
    PLoS One; 2014; 9(10):e109612. PubMed ID: 25296297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
    Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
    Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.